Developed by Incyte Corp., Opzelura is a topical nonsteroidal that is approved for patients 2 years of age and older with mild-to-moderate atopic dermatitis. It is a selective JAK1/JAK2 inhibitor that ...

An international consensus study published in JAMA Dermatology established definitions for vitiligo severity and relapse, ...

On the therapeutic front, advancements in immunology are reshaping the vitiligo treatment paradigm. Systemic and immune-modulating therapies increasingly target vitiligo, an autoimmune disease. Oral ...

Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed ...

USA: A new study has revealed that prolonged treatment with ruxolitinib cream may still lead to significant repigmentation in ...

Ruxolitinib cream can meaningfully improve skin repigmentation and QOL for patients with vitiligo, but its full benefit depends on improved patient education, guidance, and support for consistent, ...

Incyte INCY reported 54-week data from its late-stage STOP-HS program demonstrating substantial and sustained efficacy of ...

Detailed price information for Edesa Biotech Inc (EDSA-Q) from The Globe and Mail including charting and trades.

Royalty Pharma has made another play in the autoimmune space, this time crowning Johnson & Johnson as the beneficiary. Royalty and J&J have agreed to co-fund the development of a chronic autoimmune ...

A small patch, no larger than a bandage, may soon change how doctors understand the immune system. Instead of relying on ...

AbbVie (NYSE: ABBV) today announced new research across its dermatology portfolio to be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, March 27–31 in Denver, Colorado.

Program design spans eight educational tracks and more than 275 sessions, underscoring continued expansion of dermatology ...